LARYNG-O-JET KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LARYNG-O-JET KIT (LARYNG-O-JET KIT).
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
| Metabolism | Lidocaine: primarily hepatic via CYP1A2 and CYP3A4. Epinephrine: metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect. |
| Protein binding | Approximately 55% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 6–8 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Topical mucosal bioavailability is 80–100% due to direct application; negligible systemic bioavailability via oral route (<5%). |
| Onset of Action | Local application: onset within 2–5 minutes due to direct mucosal absorption. |
| Duration of Action | Clinical effect lasts 30–60 minutes after topical application, influenced by vascularity of site and drug concentration. |
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients due to risk of laryngospasm and systemic toxicity. |
| Geriatric use | Dose selection should be cautious, usually starting at the low end of the dosing range, due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LARYNG-O-JET KIT (LARYNG-O-JET KIT).
| Breastfeeding | Lidocaine excreted into breast milk; M/P ratio ~0.4-1.0. Epinephrine minimal excretion. Oral bioavailability low in infant; unlikely adverse effects at maternal therapeutic doses. Caution with high doses or prolonged use. |
| Teratogenic Risk | Lidocaine hydrochloride (20 mg/mL) and epinephrine (0.01 mg/mL) combination. Lidocaine crosses placenta; fetal:baternal ratio ~0.5-0.7. No major teratogenicity reported at standard doses; high systemic doses may cause fetal acidosis. Epinephrine may reduce uteroplacental blood flow; risk of fetal hypoxia at high doses. FDA Pregnancy Category B (lidocaine), Category C (epinephrine). First trimester: avoid high doses; second/third trimester: use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to lidocaine, epinephrine, or other amide anesthetics","Severe hypertension or cardiovascular instability","Use in areas with compromised blood supply (e.g., digits, ears, nose) due to epinephrine-induced vasoconstriction"]
| Precautions | ["Risk of systemic toxicity if excessive doses or rapid absorption occur","Use with caution in patients with hepatic impairment, cardiac disease, or hypotension","Epinephrine component may cause hypertension, tachycardia, or arrhythmias","Avoid injection into inflamed or infected tissues"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs (HR, BP, O2 sat), ECG for lidocaine toxicity (prolonged PR, QRS, CNS effects). Fetal heart rate monitoring if prolonged use or high dose. Observe for signs of local anesthetic systemic toxicity (LAST). |
| Fertility Effects | No known negative impact on fertility in animal studies; limited human data. Lidocaine and epinephrine not associated with impaired fertility at standard doses. |